Evidence map›Paper›PMID 42525959›Full record

ArticleTechnology in cancer research & treatment

GRACE-ViT: Grouped Recalibration With Adaptive Contextual Emphasis for Breast Cancer Neoadjuvant Chemotherapy Response Prediction.

Ibrahim Abdelhalim, Norah Saleh Alghamdi, Nithya Rekha Sivakumar, Shakila Basheer, Khadiga M Ali, Sohail Contractor, Ayman El-Baz

Abstract read
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ibrahim AbdelhalimBioengineering Department, J.B. Speed School of Engineering, University of Louisville, Louisville, KY, USA.ORCID 0009-0000-1544-7276
Norah Saleh AlghamdiDepartment of Computer Sciences, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Nithya Rekha SivakumarDepartment of Computer Sciences, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Shakila BasheerDepartment of Information Sciences, Princess Nourah bint Abdulrahman University, Saudi Arabia.
Khadiga M AliPathology Department, Mansoura University, Mansoura, Egypt.
Sohail ContractorDepartment of Radiology, University of Louisville, Louisville, KY, USA.
Ayman El-BazBioengineering Department, J.B. Speed School of Engineering, University of Louisville, Louisville, KY, USA.ORCID 0000-0001-7264-1323

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IntroductionAccurate prediction of neoadjuvant chemotherapy (NAC) response in breast cancer is important for treatment planning and individualized therapy selection. Breast MRI contains subtle patterns related to treatment response. These patterns vary across image regions and may be difficult for standard deep learning models to capture. In this retrospective clinical prediction model development and validation study, we propose GRACE-ViT, a Vision Transformer-based framework for three-class NAC response prediction from pre-treatment breast MRI. The three classes are partial response, complete response, and stable disease.MethodsGRACE-ViT uses a pretrained ViT backbone with a lightweight token recalibration module called Grouped Recalibration with Adaptive Contextual Emphasis (GRACE). The GRACE module refines patch-token features using dual-mode token scoring, a spatial coherence prior, and cross-group feature integration. This helps the model focus on important breast regions while keeping global image context. The model was evaluated on 736 axial T1-weighted breast MRI images. It was compared with convolutional, transformer-based, and medical-imaging models under the same preprocessing, training, validation, and testing protocol. Performance was measured using accuracy, mean F1-score, precision, and recall where bootstrap resampling was used to estimate 95% confidence intervals.ResultsGRACE-ViT reached a mean accuracy of 95.50% (95% CI: 90.99-99.10%) and a mean F1-score of 95.47% (95% CI: 91.10-99.06%). It outperformed the strongest baseline with only a small increase in computational cost. The per-class results were balanced across the three response categories, suggesting that the model did not favor one clinical outcome over another. Visual results showed that the model mainly focused on clinically relevant breast regions rather than background areas.ConclusionsThese results show that targeted token recalibration can improve ViT-based breast MRI analysis without greatly increasing model complexity, leading GRACE-ViT to provide an efficient and interpretable imaging-based approach for predicting NAC response and supporting individualized treatment decisions in breast cancer care.

Indexed as

Breast NeoplasmsNeoadjuvant TherapyDeep LearningFemaleHumansMagnetic Resonance ImagingTreatment Outcomebreast cancerdeep learningMRIneoadjuvant chemotherapyvision transformer

Identifiers

PMID42525959
PMCPMC13424510

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.